---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-035542"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-05-15T20:03:00+00:00"
generated_at: "2026-05-15T20:09:05.088476+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics CFO Adams assumes principal accounting officer; Mossler departs

## Summary
- Mark Mossler to cease as Chief Accounting Officer effective May 15, 2026; departure not due to any disagreement.
- CFO Kendra R. Adams designated as principal accounting officer, effective May 15, 2026.
- Adams receives no additional compensation for assuming the additional role.

## SEC filing metadata
- accession: 0001628280-26-035542
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-05-15T20:03:00+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/0001628280-26-035542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/cccc-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-035542
- JSON: https://secwatch.observer/filing/0001628280-26-035542.json
- Plain text: https://secwatch.observer/filing/0001628280-26-035542.txt

## Key facts
- Executive change
  Kendra R. Adams changed role as Chief Financial Officer, Head of Corporate Affairs and Treasurer at C4 Therapeutics, Inc..
  - Action: designated as principal accounting officer
  - Role: Chief Financial Officer, Head of Corporate Affairs and Treasurer
  source text: Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/0001628280-26-035542-index.htm
- Executive change
  Mark Mossler departed as Chief Accounting Officer at C4 Therapeutics, Inc..
  - Action: will no longer serve
  - Role: Chief Accounting Officer
  source text: Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/0001628280-26-035542-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.